Skip to main content

Table 1 Clinical characteristics between the two groups

From: Effect of sitagliptin on the echocardiographic parameters of left ventricular diastolic function in patients with type 2 diabetes: a subgroup analysis of the PROLOGUE study

Variables Baseline 24 months Least square means of baseline-adjusted changes
Sitagliptin (n = 55) Conventional (n = 60) p value Sitagliptin (n = 55) Conventional (n = 60) p value Sitagliptin (n = 55) Conventional (n = 60) p value
Age, year 69 ± 8 69 ± 9 0.973       
Gender (male/female) 38/17 39/21 0.641       
Body mass index, kg/m2 25.9 ± 3.3 24.8 ± 3.9 0.098 25.5 ± 3.4 24.6 ± 3.8 0.203 −0.10 ± 0.16 −0.13 ± 0.15 0.368
Systolic BP, mmHg 132 ± 17 129 ± 19 0.287 133 ± 16 130 ± 20 0.377 1.70 ± 2.20 (n = 54) 0.34 ± 2.09 0.656
Diastolic BP, mmHg 74 ± 11 71 ± 12 0.090 75 ± 13 (n = 54) 71 ± 11 0.076 1.76 ± 1.47 (n = 54) −0.54 ± 1.40 0.263
Heart rate, beats/min 70 ± 12 67 ± 12 0.196 71 ± 16 67 ± 10 0.129 3.37 ± 1.49 −2.14 ± 1.43 0.009
Total cholesterol, mmol/L 4.4 ± 0.8 4.6 ± 0.9 0.43 4.4 ± 0.8 (n = 54) 4.4 ± 1.0 0.690 −0.08 ± 0.09 (n = 54) −0.10 ± 0.08 0.899
HDL cholesterol, mmol/L 1.3 ± 0.3 (n = 55) 1.4 ± 0.4 (n = 58) 0.617 1.3 ± 0.3 (n = 54) 1.4 ± 0.4 0.412 −0.03 ± 0.03 (n = 54) 0.00 ± 0.03 (n = 58) 0.362
Triglycerides, mmol/L 3.1 [2.2–4.5] (n = 54) 3.1 [2.3–4.2] 0.536 2.9 [2.2–5.0] (n = 54) 2.9 [2.1–3.9] 0.151 0.06 ± 0.06 (n = 53) −0.08 ± 0.05 0.078
Creatinine, μmol/L 71.6 [61.9–86.6] 68.1 [59.2–89.3] 0.496 75.1 [62.8–87.5] (n = 54) 69.0 [61.0–98.1] 0.740 2.65 ± 1.77 (n = 54) 4.42 ± 1.77 0.345
eGFR, mL/min/1.73 m2 66.6 ± 15.9 67.3 ± 18.4 0.834 65.1 ± 14.1 (n = 54) 67.1 ± 19.7 0.757 −1.96 ± 1.10 (n = 54) –3.18 ± 1.04 0.419
Fasting plasma glucose, mmol/L 7.5 ± 1.8 (n = 53) 7.1 ± 1.4 0.135 7.0 ± 1.6 (n = 54) 6.7 ± 1.7 (n = 58) 0.248 −0.41 ± 0.20 (n = 52) −0.49 ± 0.19 (n = 58) 0.780
HbA1c, % 7.0 ± 0.6 6.9 ± 0.5 0.737 6.5 ± 0.6 (n = 54) 6.6 ± 0.7 0.412 −0.47 ± 0.08 (n = 52) −0.34 ± 0.07 (n = 57) 0.211
1,5AG, µg/mL 13.9 [8.3–20.3] (n = 52) 15.6 [10.7–22.8] (n = 58) 0.086 16.4 [8.7–22.6] 15.1 [9.6–25.0] (n = 59) 0.747 2.55 ± 0.82 (n = 52) 0.95 ± 0.79 (n = 57) 0.165
NT-proBNP, pg/mL 111.5 [42.1–240.8] (n = 52) 99.6 [52.1–234.9] (n = 58) 0.848 114.5 [51.8–261.9] 114.1 [60.2–323.8] (n = 59) 0.673 0.09 ± 0.08 (n = 52) 0.16 ± 0.08 (n = 57) 0.535
High-sensitive CRP, ng/mL 540 [279–1100] (n = 52) 576 [236–1618] (n = 58) 0.952 478 [232–1150] (n = 55) 478 [199–1590] (n = 59) 0.984 −0.06 ± 0.16 (n = 52) −0.06 ± 0.15 (n = 57) 0.983
Current smoker, n (%) 8 (17.4) (n = 46) 13 (28.3) (n = 46) 0.321       
Hypertension, n (%) 45 (81.8) 46 (76.7) 0.497       
Dyslipidemia, n (%) 42 (76.4) 42 (70.0) 0.530       
Cerebrovascular disease, n (%) 8 (14.6) 4 (6.7) 0.226       
Cardiovascular disease, n (%) 38 (69.1) 41 (68.3) 0.930       
Chronic heart failure, n (%) 3 (5.5) 7 (11.7) 0.326       
Medications
 ACE inhibitor or ARB 37 (67.3) 42 (70.0) 0.753 39 (70.9) 41 (68.3) 0.764    
 β-blocker 12 (21.8) 11 (18.3) 0.641 13 (23.6) 12 (20.0) 0.637    
 Diuretic 17 (30.9) 12 (20.0) 0.178 16 (29.1) 15 (25.0) 0.621    
 Statin 42 (76.4) 40 (66.7) 0.251 39 (70.9) 39 (65.0) 0.498    
 α-Glucosidase inhibitor, n (%) 23 (41.8) 30 (50.0) 0.455 18 (32.7) 38 (63.3) 0.001    
 Glinide, n (%) 4 (7.3) 4 (6.7) 0.899 2 (3.6) 5 (8.3) 0.293    
 Biguanide, n (%) 9 (16.4) 10 (16.7) 0.965 12 (21.8) 16 (26.7) 0.545    
 Sulfonylurea, n (%) 9 (16.4) 12 (20.0) 0.638 4 (7.3) 18 (30.0) 0.002    
 Thiazolidinedione, n (%) 11 (20.0) 18 (30.0) 0.283 9 (16.4) 23 (38.3) 0.009    
  1. Data for categorical variables are given as number (%); data for continuous variables given as mean ± standard deviation or median [interquartile range]. Skewed data was calculated after logarithmic translation. In the right column, values are shown as baseline-adjusted least square mean ± standard error
  2. BP blood pressure, HDL high-density lipoprotein, eGFR estimated glomerular filtration rate, 1,5AG 1,5-anhydroglucitol,1,4-anhydro-d-glucitol, NT-proBNP N-terminal pro-brain natriuretic peptide, CRP C-reactive protein. ACE angiotensin-converting enzyme, ARB angiotensin receptor blocker